05:46 AM EDT, 05/02/2025 (MT Newswires) -- Eli Lilly ( LLY ) brushed off concerns about the impact of CVS Health's ( CVS ) decision to drop coverage of Lilly's Zepbound weight-loss drug from some of its health plans while retaining rival Novo Nordisk's ( NVO ) Wegovy.

"We're not surprised that this kind of thing was announced," Lilly Chief Executive David Ricks said on an earnings conference call Thursday, according to a FactSet transcript. "We're not interested at all in one-of-one deals of reducing access and choice for doctors and patients."

CVS did not immediately reply to MT Newswires' request for comment.

Lilly shares were up 2.4% in recent premarket activity Friday after closing nearly 12% lower Thursday.